• Test code: 08160
  • Turnaround time:
    10–21 calendar days (14 days on average)
  • Preferred specimen:
    3mL whole blood in a purple-top tube
  • Alternate specimens:
    DNA or saliva/assisted saliva
  • Sample requirements
  • Request a sample kit

Invitae Phagocyte Defects Panel

Test description

This test analyzes up to 27 genes that are associated with hereditary phagocyte defects (HPD). Genetic testing of these genes may confirm a diagnosis and help guide treatment and management decisions. Identification of a disease-causing variant would also guide testing and diagnosis of at-risk relatives. This test is specifically designed for heritable germline mutations and is not appropriate for the detection of somatic mutations.

If the patient has undergone a bone marrow transplant prior to genetic testing testing a sample type not derived from blood (such as skin biopsy) is warranted. While we do not accept this sample type directly, we can accept gDNA derived from skin or muscle, but deletion/duplication analysis is not guaranteed for gDNA samples because the success rate varies based on sample quality. Please see our Specimen Requirements page for more details.

Note: The NCF1 gene is not offered in this panel.

Order test

Primary panel (27 genes)


Hereditary phagocyte defects (HPD) including:

Gene Disorder Protein name Protein symbol
CEBPE Specific granule deficiency C/EBP-epsilon C/EBP
CLPB 3-Methylglutaconic aciduria caseinolytic peptidase B CLPB
CSF2RA Pulmonary alveolar proteinosis granulocyte/macrophage colony-stimulating factor GMCSF
CSF3R G-CSF receptor deficiency granulocyte colony-stimulating factor receptor CSF3R
CTSC Papillon-Lefèvre Syndrome cathepsin C CTSC
CYBA Autosomal recessive CGD 22kD-phagocyte oxidase p22-phox
CYBB X-linked CGD 91kD-phagocyte oxidase p91-phox
ELANE Elastase deficiency (SCN1), cyclic neutropenia elastase ELANE
FERMT3 Leukocyte adhesion deficiency type 3 KINDLIN3 KINDLIN3
FPR1 Localized juvenile periodontitis Formylated peptide receptor FPR1
G6PC3 G6PC3 deficiency (SCN4) glucose-6-phosphatase beta G6PC3
G6PD Neutrophil G6PD deficiency glucose-6-phosphate dehydrogenase G6PD
GFI1 GFI 1 deficiency (SCN2) growth factor-independent 1 GFI1
HAX1 Kostmann Disease (SCN3) HCLS1-associated protein X1 HAX1
ITGB2 Leukocyte adhesion deficiency type 1 integrin beta 2 ITGB2
JAGN1 JAGN1 deficiency homolog of drosophila jagunal 1 JAGN1
LAMTOR2 P14/LAMTOR2 deficiency p14 P14
NCF2 Autosomal recessive CGD 67kD-phagocyte oxidase p67-phox
NCF4 Autosomal recessive CGD 40kD-phagocyte oxidase p40-phox
PMM2 PMM2-congenital disorder of glycosylation (CDG-Ia) Phosphomannomutase PMM2
SLC35C1 Leukocyte adhesion deficiency type 2 GDP-fucose transporter 1 SLC35C1
SLC37A4 Glycogen storage disease type 1b glucose-6-phosphate transporter 1 G6PT1
SPINK5 Comel-Netherton syndrome lymphoepithelial kazal type related inhibitor LEKT1
TAZ Barth syndrome tafazzin TAZ
VPS13B Cohen syndrome vacuolar protein sorting 13 homolog B COH1
VPS45 VPS45 deficiency (SCN5) vaculolar protein sorting 45 VPS45
WAS Wiskott-Aldrich syndrome, X-linked neutropenia/ myelodysplasia WAS protein WASP

Phagocytes are the body’s first defense against invading microorganisms. Hereditary genetic changes that affect the number and function of phagocytes can increase the risk for life threatening bacterial and fungal infections, mainly of the soft tissues. Most phagocytic disorders can be broken down into three main types: chronic granulomatous disease, congenital phagocyte defects and leukocyte adhesion deficiency. While most symptoms of HPD appear during the first year of life, some individuals can have later age of onset. Approximately 8% of primary immunodeficiencies are the result of a phagocytic disorder. Penetrance is complete for most types of HPD.

Determination of an underlying genetic predisposition in an individual with a personal or family history of HPD is critical for the selection of therapy regimens, consideration of bone marrow or stem cell transplant, and counseling of the individual and their family.

The following genes confer an increased risk of HPD in:

  • an autosomal dominant inheritance pattern – ELANE, FPR1, GFI1
  • an autosomal recessive inheritance pattern – CEBPE, CLPB, CTSC, CYBA, FERMT3, G6PC3, HAX1, ITGB2, JAGN1, LAMTOR2, NCF2, NCF4, PMM2, SLC35C1, SLC37A4, SPINK5, VPS13B, VPS45
  • an autosomal dominant or autosomal recessive inheritance pattern – CSF3R
  • an X-linked inheritance pattern – CYBB, G6PD, TAZ, WAS
  • CSF2RA is found on the pseudoautosomal region on the X and Y chromosomes. Biallelic pathogenic variants cause disease

This panel may be considered for individuals whose personal and/or family history is suggestive of a hereditary predisposition to phagocyte defects, including any of the following:

  • chronic common bacterial and fungal infections
  • unusual bacterial and fungal infections
  • omphalitis in infants
  • congenital neutropenia
  • a family history of HPD

If the patient has undergone a bone marrow transplant prior to genetic testing testing a sample type not derived from blood (such as skin biopsy) is warranted. While we do not accept this sample type directly, we can accept gDNA derived from skin or muscle, but deletion/duplication analysis is not guaranteed for gDNA samples because the success rate varies based on sample quality. Please see our Specimen Requirements for more details.

  1. Capo-Chichi, JM, et al. Disruption of CLPB is associated with congenital microcephaly, severe encephalopathy and 3-methylglutaconic aciduria. J. Med. Genet. 2015; 52(5):303-11. PMID: 25650066
  2. Wortmann, SB, et al. CLPB mutations cause 3-methylglutaconic aciduria, progressive brain atrophy, intellectual disability, congenital neutropenia, cataracts, movement disorder. Am. J. Hum. Genet. 2015; 96(2):245-57. PMID: 25597510
  3. Saunders, C, et al. CLPB variants associated with autosomal-recessive mitochondrial disorder with cataract, neutropenia, epilepsy, and methylglutaconic aciduria. Am. J. Hum. Genet. 2015; 96(2):258-65. PMID: 25597511
  4. Reust, CE. Evaluation of primary immunodeficiency disease in children. Am Fam Physician. 2013; 87(11):773-8. PMID: 23939499
  5. Triot, A, et al. Inherited biallelic CSF3R mutations in severe congenital neutropenia. Blood. 2014; 123(24):3811-7. PMID: 24753537
  6. Klimiankou, M, et al. GM-CSF stimulates granulopoiesis in a congenital neutropenia patient with loss-of-function biallelic heterozygous CSF3R mutations. Blood. 2015; 126(15):1865-7. PMID: 26324699
  7. Makaryan, V, et al. The diversity of mutations and clinical outcomes for ELANE-associated neutropenia. Curr. Opin. Hematol. 2015; 22(1):3-11. PMID: 25427142
  8. Banka, S, Newman, WG. A clinical and molecular review of ubiquitous glucose-6-phosphatase deficiency caused by G6PC3 mutations. Orphanet J Rare Dis. 2013; 8:84. PMID: 23758768
  9. Boztug, K, et al. A syndrome with congenital neutropenia and mutations in G6PC3. N. Engl. J. Med. 2009; 360(1):32-43. PMID: 19118303
  10. Dursun, A, et al. Familial pulmonary arterial hypertension, leucopenia, and atrial septal defect: a probable new familial syndrome with multisystem involvement. Clin. Dysmorphol. 2009; 18(1):19-23. PMID: 19011569
  11. Banka, S, et al. Mutations in the G6PC3 gene cause Dursun syndrome. Am. J. Med. Genet. A. 2010; 152A(10):2609-11. PMID: 20799326
  12. Klein, C. Congenital neutropenia. Hematology Am Soc Hematol Educ Program. 2009; :344-50. PMID: 20008220
  13. Welte, K, et al. Severe congenital neutropenia. Semin. Hematol. 2006; 43(3):189-95. PMID: 16822461
  14. Klein, C. Genetic defects in severe congenital neutropenia: emerging insights into life and death of human neutrophil granulocytes. Annu. Rev. Immunol. 2011; 29:399-413. PMID: 21219176
  15. Mamishi, S, et al. Severe congenital neutropenia in 2 siblings of consanguineous parents. The role of HAX1 deficiency. J Investig Allergol Clin Immunol. 2009; 19(6):500-3. PMID: 20128427
  16. Eghbali, A, et al. HAX1 mutation in an infant with severe congenital neutropenia. Turk. J. Pediatr. 2010; 52(1):81-4. PMID: 20402072
  17. Patiroglu, T, et al. Severe congenital neutropenia in two siblings related to HAX1 mutation without neurodevelopmental disorders. Genet. Couns. 2013; 24(3):253-8. PMID: 24341138
  18. Stieglitz, E, Loh, ML. Genetic predispositions to childhood leukemia. Ther Adv Hematol. 2013; 4(4):270-90. PMID: 23926459
  19. Germeshausen, M, et al. Novel HAX1 mutations in patients with severe congenital neutropenia reveal isoform-dependent genotype-phenotype associations. Blood. 2008; 111(10):4954-7. PMID: 18337561
  20. Carlsson, G, et al. Central nervous system involvement in severe congenital neutropenia: neurological and neuropsychological abnormalities associated with specific HAX1 mutations. J. Intern. Med. 2008; 264(4):388-400. PMID: 18513342
  21. Boztug, K, et al. HAX1 mutations causing severe congenital neuropenia and neurological disease lead to cerebral microstructural abnormalities documented by quantitative MRI. Am. J. Med. Genet. A. 2010; 152A(12):3157-63. PMID: 21108402
  22. Boztug, K, et al. JAGN1 deficiency causes aberrant myeloid cell homeostasis and congenital neutropenia. Nat. Genet. 2014; 46(9):1021-7. PMID: 25129144
  23. Baris, S, et al. JAGN1 Deficient Severe Congenital Neutropenia: Two Cases from the Same Family. J. Clin. Immunol. 2015; 35(4):339-43. PMID: 25851723
  24. Bohn, G, et al. A novel human primary immunodeficiency syndrome caused by deficiency of the endosomal adaptor protein p14. Nat. Med. 2007; 13(1):38-45. PMID: 17195838
  25. Steward, CG, et al. Barth syndrome: an X-linked cause of fetal cardiomyopathy and stillbirth. Prenat. Diagn. 2010; 30(10):970-6. PMID: 20812380
  26. Clarke, SL, et al. Barth syndrome. Orphanet J Rare Dis. 2013; 8:23. PMID: 23398819
  27. Saric, A, et al. Barth Syndrome: From Mitochondrial Dysfunctions Associated with Aberrant Production of Reactive Oxygen Species to Pluripotent Stem Cell Studies. Front Genet. 2015; 6:359. PMID: 26834781
  28. van, Werkhoven, MA, et al. Monolysocardiolipin in cultured fibroblasts is a sensitive and specific marker for Barth Syndrome. J. Lipid Res. 2006; 47(10):2346-51. PMID: 16873891
  29. Angelini, R, et al. Cardiolipin fingerprinting of leukocytes by MALDI-TOF/MS as a screening tool for Barth syndrome. J. Lipid Res. 2015; 56(9):1787-94. PMID: 26144817
  30. Roberts, AE, et al. The Barth Syndrome Registry: distinguishing disease characteristics and growth data from a longitudinal study. Am. J. Med. Genet. A. 2012; 158A(11):2726-32. PMID: 23045169
  31. Vilboux, T, et al. A congenital neutrophil defect syndrome associated with mutations in VPS45. N. Engl. J. Med. 2013; 369(1):54-65. PMID: 23738510
  32. Stepensky, P, et al. The Thr224Asn mutation in the VPS45 gene is associated with the congenital neutropenia and primary myelofibrosis of infancy. Blood. 2013; 121(25):5078-87. PMID: 23599270
  33. Meerschaut, I, et al. Severe congenital neutropenia with neurological impairment due to a homozygous VPS45 p.E238K mutation: A case report suggesting a genotype-phenotype correlation. Am. J. Med. Genet. A. 2015; 167A(12):3214-8. PMID: 26358756
  34. Buchbinder, D, et al. Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments. Appl Clin Genet. 2014; 7:55-66. PMID: 24817816
  35. Boonyawat, B, et al. Combined de-novo mutation and non-random X-chromosome inactivation causing Wiskott-Aldrich syndrome in a female with thrombocytopenia. J. Clin. Immunol. 2013; 33(7):1150-5. PMID: 23943155
  36. van, de, Vijver, E, et al. Hematologically important mutations: leukocyte adhesion deficiency (first update). Blood Cells Mol. Dis. 2012; 48(1):53-61. PMID: 22134107
  37. Hanna, S, Etzioni, A. Leukocyte adhesion deficiencies. Ann. N. Y. Acad. Sci. 2012; 1250:50-5. PMID: 22276660
  38. Madkaikar, M, et al. Molecular characterization of leukocyte adhesion deficiency-I in Indian patients: identification of 9 novel mutations. Blood Cells Mol. Dis. 2015; 54(3):217-23. PMID: 25703682
  39. Kuijpers, TW, et al. LAD-1/variant syndrome is caused by mutations in FERMT3. Blood. 2009; 113(19):4740-6. PMID: 19064721
  40. Malinin, NL, et al. A point mutation in KINDLIN3 ablates activation of three integrin subfamilies in humans. Nat. Med. 2009; 15(3):313-8. PMID: 19234460
  41. Hidalgo, A, et al. Insights into leukocyte adhesion deficiency type 2 from a novel mutation in the GDP-fucose transporter gene. Blood. 2003; 101(5):1705-12. PMID: 12406889
  42. Helmus, Y, et al. Leukocyte adhesion deficiency II patients with a dual defect of the GDP-fucose transporter. Blood. 2006; 107(10):3959-66. PMID: 16455955
  43. Bohler, MC, et al. A study of 25 patients with chronic granulomatous disease: a new classification by correlating respiratory burst, cytochrome b, and flavoprotein. J. Clin. Immunol. 1986; 6(2):136-45. PMID: 3011845
  44. Johnston, RB. Clinical aspects of chronic granulomatous disease. Curr. Opin. Hematol. 2001; 8(1):17-22. PMID: 11138621
  45. Chiriaco, M, et al. Chronic granulomatous disease: Clinical, molecular, and therapeutic aspects. Pediatr Allergy Immunol. 2016; 27(3):242-53. PMID: 26680691
  46. Kragballe, K, et al. Relation of monocyte and neutrophil oxidative metabolism to skin and oral lesions in carriers of chronic granulomatous disease. Clin. Exp. Immunol. 1981; 43(2):390-8. PMID: 7273485
  47. Finlay, AY, et al. Chronic granulomatous disease carrier geno-dermatosis (CGDCGD). Clin. Genet. 1983; 23(4):276-80. PMID: 6851217
  48. Bustamante, J, et al. A novel X-linked recessive form of Mendelian susceptibility to mycobaterial disease. J. Med. Genet. 2007; 44(2):e65. PMID: 17293536
  49. Bustamante, J, et al. Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease. Nat. Immunol. 2011; 12(3):213-21. PMID: 21278736
  50. Trapnell, BC, et al. Pulmonary alveolar proteinosis. N. Engl. J. Med. 2003; 349(26):2527-39. PMID: 14695413
  51. Clark, H, Clark, LS. The genetics of neonatal respiratory disease. Semin Fetal Neonatal Med. 2005; 10(3):271-82. PMID: 15927881
  52. Hildebrandt, J, et al. Characterization of CSF2RA mutation related juvenile pulmonary alveolar proteinosis. Orphanet J Rare Dis. 2014; 9:171. PMID: 25425184
  53. Suzuki, T, et al. Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J. Exp. Med. 2008; 205(12):2703-10. PMID: 18955570
  54. Martinez-Moczygemba, M, et al. Pulmonary alveolar proteinosis caused by deletion of the GM-CSFRalpha gene in the X chromosome pseudoautosomal region 1. J. Exp. Med. 2008; 205(12):2711-6. PMID: 18955567
  55. Suzuki, T, et al. Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy. Am. J. Respir. Crit. Care Med. 2010; 182(10):1292-304. PMID: 20622029
  56. Hart, TC, et al. Localisation of a gene for prepubertal periodontitis to chromosome 11q14 and identification of a cathepsin C gene mutation. J. Med. Genet. 2000; 37(2):95-101. PMID: 10662808
  57. Hart, TC, et al. Genetic studies of syndromes with severe periodontitis and palmoplantar hyperkeratosis. J. Periodont. Res. 1997; 32(1 Pt 2):81-9. PMID: 9085215
  58. Ullbro, C, et al. Dermatologic and oral findings in a cohort of 47 patients with Papillon-Lefèvre syndrome. J. Am. Acad. Dermatol. 2003; 48(3):345-51. PMID: 12637913
  59. Gwinn, MR, et al. Single nucleotide polymorphisms of the N-formyl peptide receptor in localized juvenile periodontitis. J. Periodontol. 1999; 70(10):1194-201. PMID: 10534074
  60. Gunji, T, et al. Functional polymorphisms of the FPR1 gene and aggressive periodontitis in Japanese. Biochem. Biophys. Res. Commun. 2007; 364(1):7-13. PMID: 17927965
  61. Cappellini, MD, Fiorelli, G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008; 371(9606):64-74. PMID: 18177777
  62. Watchko, JF. Common hematologic problems in the newborn nursery. Pediatr. Clin. North Am. 2015; 62(2):509-24. PMID: 25836711
  63. Grünewald, S. The clinical spectrum of phosphomannomutase 2 deficiency (CDG-Ia). Biochim. Biophys. Acta. 2009; 1792(9):827-34. PMID: 19272306
  64. Vuillaumier-Barrot, S, et al. Expanding the Spectrum of PMM2-CDG Phenotype. JIMD Rep. 2012; 5:123-5. PMID: 23430927
  65. Monin, ML, et al. 29 French adult patients with PMM2-congenital disorder of glycosylation: outcome of the classical pediatric phenotype and depiction of a late-onset phenotype. Orphanet J Rare Dis. 2014; 9:207. PMID: 25497157
  66. Barone, R, et al. A nationwide survey of PMM2-CDG in Italy: high frequency of a mild neurological variant associated with the L32R mutation. J. Neurol. 2015; 262(1):154-64. PMID: 25355454

Assay and technical information

Invitae is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified clinical diagnostic laboratory performing full-gene sequencing and deletion/duplication analysis using next-generation sequencing technology (NGS).

Our sequence analysis covers clinically important regions of each gene, including coding exons, +/- 10 base pairs of adjacent intronic sequence in the transcript listed below. In addition, analysis covers the select non-coding variants specifically defined in the table below. Any variants that fall outside these regions are not analyzed. Any specific limitations in the analysis of these genes are also listed in the table below.

Based on validation study results, this assay achieves >99% analytical sensitivity and specificity for single nucleotide variants, insertions and deletions <15bp in length, and exon-level deletions and duplications. Invitae's methods also detect insertions and deletions larger than 15bp but smaller than a full exon but sensitivity for these may be marginally reduced. Invitae’s deletion/duplication analysis determines copy number at a single exon resolution at virtually all targeted exons. However, in rare situations, single-exon copy number events may not be analyzed due to inherent sequence properties or isolated reduction in data quality. Certain types of variants, such as structural rearrangements (e.g. inversions, gene conversion events, translocations, etc.) or variants embedded in sequence with complex architecture (e.g. short tandem repeats or segmental duplications), may not be detected. Additionally, it may not be possible to fully resolve certain details about variants, such as mosaicism, phasing, or mapping ambiguity. Unless explicitly guaranteed, sequence changes in the promoter, non-coding exons, and other non-coding regions are not covered by this assay. Please consult the test definition on our website for details regarding regions or types of variants that are covered or excluded for this test. This report reflects the analysis of an extracted genomic DNA sample. In very rare cases, (circulating hematolymphoid neoplasm, bone marrow transplant, recent blood transfusion) the analyzed DNA may not represent the patient's constitutional genome.

Gene Transcript reference Sequencing analysis Deletion/Duplication analysis
CEBPE NM_001805.3
CLPB NM_030813.5
CSF2RA* NM_006140.4
CSF3R NM_000760.3
CTSC NM_001814.5
CYBA NM_000101.3
CYBB NM_000397.3
ELANE NM_001972.2
FERMT3 NM_031471.5
FPR1 NM_002029.3
G6PC3 NM_138387.3
G6PD NM_001042351.2
GFI1 NM_005263.3
HAX1 NM_006118.3
ITGB2 NM_000211.4
JAGN1 NM_032492.3
LAMTOR2 NM_014017.3
NCF2 NM_000433.3
NCF4 NM_013416.3
PMM2 NM_000303.2
SLC35C1 NM_018389.4
SLC37A4 NM_001164277.1
SPINK5 NM_006846.3
TAZ NM_000116.4
VPS13B NM_017890.4
VPS45 NM_007259.4
WAS NM_000377.2

CSF2RA: Deletion/duplication analysis is not offered for this gene.